Enveric Biosciences appoints Robert Dickey IV as interim CFO effective Sept 9, 2022

Enveric Biosciences, Inc.

Robert Dickey IV, age 66, appointed as interim CFO effective September 9, 2022.
Mr. Dickey is Managing Director at Foresite Advisors, providing finance support for life science companies.
Previously served as CFO of Motif Bio Plc (2017-2018) and Tyme Technologies (2015-2017).
He holds an MBA from Wharton and a BA from Princeton.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Robert Dickey IV

Chief Financial Officer

ENVB · Enveric Biosciences, Inc.

Effective: 2022-09-09
Filed: September 13, 2022, 7:59 PM ET

On September 9, 2022, Robert Dickey IV was appointed as the Chief Financial Officer (“CFO”) of the Company, to serve on an interim basis, effective September 9, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert Dickey IV was appointed as Chief Financial Officer at Enveric Biosciences, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On September 9, 2022, Robert Dickey IV was appointed as the Chief Financial Officer (“CFO”) of the Company, to serve on an interim basis, effective September 9, 2022.

View on SEC.gov

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-025724

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.